MEMO1

Across TCGA pan-cancer cohorts, MEMO1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MEMO1 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MEMO1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MEMO1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, GBM, and LUAD are the cancer types where MEMO1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	II,III,IV	0.940	0.663	<.001	53	view →
GBM	DFS	Tertile	All	0.593	0.875	.003	26	view →
LUAD	OS	Quartile	III,IV	0.133	0.787	.001	13	view →
CCRCC	OS	Quartile	All	0.533	1.000	.015	12	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.843	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MEMO1–HNSC (DFS)

Open the HNSC breakdown →